Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG01 + T517
- Development stage
- Phase 3
- Lead developer
- Inmunotek
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
MG01 + T517 is a subcutaneous allergen immunotherapy developed by Inmunotek for the treatment of allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma. It consists of a purified and polymerized glutaraldehyde allergen extract derived from a mixture of grass pollens (including Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne, Dactylis glomerata) and olive pollen (Olea europaea). The therapy acts as an immunomodulator to induce immune tolerance to these allergens. It is currently in phase III clinical trials in Spain for multiple age groups with indications including allergic rhinitis and asthma[1][3][4].
- Other names
- 10,000 MG01 + 10,000 T51730,000 MG01 + 10,000 T517
02
Targets
Olive pollen allergensPhleum pratense allergens
Beyond the preview
Go deeper on MG01 + T517.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG01 + T517.